Foundation

OAFI is the Osteoarthritis Foundation International, the first and only worldwide foundation exclusively devoted to the people living with osteoarthritis.

Created in October 2016 in Barcelona, the Foundation’s goal is to lead the fight against osteoarthritis by promoting education, prevention, treatment and research on those areas pertaining to joint health and to offer solutions to those suffering from this pathology so that they can feel accompanied, relieve their pain and improve their quality of life.

While a broadly unrecognized condition, osteoarthritis currently affects over 300 million people worldwide. Despite its social impact, it is considered as a distant pathology only associated with old age. However, besides affecting the elderly, it is increasingly detected in postmenopausal women, sports people and even young people.

Osteoarthritis directly affects the mobility of patients and their autonomy, with the psychological wear and tear that this entails. In addition, it is associated with other comorbidity problems such as hypertension or cardiovascular diseases, among others.

In a society where the population’s life expectancy is on the rise, this type of illness should be considered as a first-rate concern. This is the reason why the Osteoarthritis Foundation International works to put the patient at the center of the disease and to help him or her have a voice and be heard. All our actions are designed for the benefit of the patient and for the prevention of osteoarthritis in people with higher risk factors.

Investigation

OAFI is an independent non-profit foundation aimed at promoting scientific research in the field of osteoarthritis to improve the quality of life of the people who suffer from this condition. In addition, it undertakes awareness-raising programs on the disease to sensitize society and reduce the number of people affected by it.

radiografia-KOA
gente-mayor-activa

Improve Life Quality

With the increase in life expectancy and the aging of the population, osteoarthritis presents an increasingly worrying trend, which is why, the Foundation has launched several projects and activities aimed at society in general, as well as Osteoarthritis patients in particular.

Our Commitment

The commitment, honesty, respect, integrity and transparency of Osteoarthritis Foundation International (OAFI) towards society reflect our effort in reaching our goals. As such, we are happy to share information about our activities, the status of our projects and research, as well as our accounts.

BAIXA (2)
Dr. Josep Vergés, a medical professional with extensive experience in the disease and international reputation, is the president of OAFI.
The OAFI team, strives to increase awareness about OA and to find the best preventive and therapeutic measures to improve the quality of life of OA patients worldwide. The OAFI team welcomes you to a world of joint health and invites you to join the OAFI family.

Team

Dr. Josep Vergés Milano

Dr. Josep Vergés Milano
President & CEO
Investigation Area

equipo-maria-teresa

María Teresa Vergés Milano
Patients Area

equipo-marco

Marco Bibas Castany
Operations Area

marianna

MARIANNA VITALONI
Science, Research & Innovation Area

Ingrid Rovira

INGRID ROVIRA
Communication Area

Board

JV-pare

Josep Vergés Monturiol

DrVerges-Portfolio

Dr. Josep Vergés Milano
President

Jordi-Ramentol-Portfolio

Jordi Ramentol Massana

Marco_Bibas

Marco Bibas Castany
Board Secretary

patronato-ribas

Maria Ribas Siñol

Transparency

The OAFI Foundation is a private foundation established for an indefinite period under the registered name of the Osteoarthritis Foundation International (OAFI) on February 25th, 2016. Subjected to the Third Book of the Civil Code of Catalonia, it is registered in the Registry of Foundations of the Generalitat of Catalonia with number 2965.

The Foundation is ruled in accordance with Title III, Chapter I, Article 16 of Spanish Law 49/2002, of December 23, of tax regime of non-profit entities and fiscal incentives for patronage.

In 2017 the members of the board of trustees did not receive any kind of remuneration from the OAFI Foundation because of their post. Likewise, they did not receive any kind of advance or credit during the year.

You can download the latest Annual Report and financial information below: OAFI Annual Report 2018

STATEMENT OF ENTITIES AND COMPANIES COLLABORATING WITH OAFI

The entities and companies with which OAFI has collaborated in the year 2019 are listed below:

  • Ajuntament de Barcelona
  • Athletic Club
  • Atlético de Madrid
  • Amgen
  • Advanced Sport & Nutritions Lab (AS&NL)
  • Arthritis Foundation
  • Alianza General de Pacientes (AGP)
  • Asociación Española con la Osteoporosis y la Artrosis (AECOSAR)
  • Bioiberica
  • Clínica CEMTRO
  • Clínica Diagonal
  • Clínica DKF
  • Clubs DiR
  • Conex
  • Diputació de Barcelona
  • Eurecat
  • Ferrer Internacional
  • FGC Ferrocarrils
  • Fundación García Cugat
  • Fundación UBAE
  • Fundación Walkim

  • Fútbol Club Barcelona
  • Gebro Pharma
  • Goco (Amigables)
  • Hifas da Terra
  • Ibsa
  • ICARO birding experience
  • Instituto Fundación Teófilo Hernando
  • Instituto Poal de Reumatología
  • Kern Pharma
  • Laboratorios ORDESA
  • Leitat
  • Looper
  • Lucta
  • Lyposmol
  • Ma d’Or
  • Mémora
  • Merck
  • MMC Intellectual Property Institute
  • Nou Cant
  • Nutra OTC

  • Opko Health Europe
  • Pan-American League of Rheumatology Associations (PANLAR)
  • Pfizer Lilly
  • Procare Health
  • Proteïn
  • Reig Jofre
  • Senior Iuris
  • Sermes
  • Servei de Desenvolupament del Medicament
  • Servier
  • Sociedad Española de Calidad Asistencial (SECA)
  • Sociedad Española de Farmacia Familiar y Comunitaria (SEFAC)
  • Sociedad Española de Médicos de Atención Primaria (SEMERGEN)
  • Sociedad Española de Médicos Generales y de Familia (SEMG)
  • Sociedad Española de Reumatología (SER)
  • Sociedad Española de Traumatología del Deporte (SETRADE)
  • Solutex
  • Transports Metropolitans de Barcelona (TMB)
  • Universitat de Barcelona (UB)
  • World Scleroderma Foundation

Help us improve the quality of life of osteoarthritis patients.